Silk polymer-based adenosine release: therapeutic potential for epilepsy
The invention provides formulations comprising adenosine in a silk fibroin-based, sustained-release delivery system. The formulations provide sustained, focal release of adenosine at therapeutic levels for the treatment of epilepsy and/or the prevention of epileptogenesis.
1. A biocompatible, biodegradable, sustained-release implantable pharmaceutical composition comprising adenosine in a silk fibroin-based, sustained-release delivery system, wherein the silk fibroin-based, sustained delivery system comprises adenosine-encapsulating microspheres embedded in a silk fibroin scaffold and wherein the scaffold further comprises adenosine which is not encapsulated in the microspheres, wherein upon implantation said implantable pharmaceutical composition has been shown in reference subjects to release from about 200 ng adenosine per day to about 10 mg adenosine per day, inclusive, for at least eight consecutive days.
2. The biocompatible, biodegradable sustained-release implantable pharmaceutical composition of claim 1 , wherein upon implantation said implantable pharmaceutical composition has been shown in reference subjects to release from about 800 ng adenosine per day to about 1100 ng adenosine per day, inclusive, for at least eight consecutive days.
3. The biocompatible, biodegradable sustained-release implantable pharmaceutical composition of claim 1 , wherein upon implantation said implantable pharmaceutical composition has been shown in reference subjects to release from about 200 ng adenosine per day to about 5 mg adenosine per day, inclusive, for at least eight consecutive days.
4. The biocompatible, biodegradable sustained-release implantable pharmaceutical composition of claim 1 , wherein upon implantation, the implantable composition has been shown in reference subjects to release from about 1 mg adenosine per day to about 10 mg adenosine per day, inclusive, for at least eight consecutive days.
5. The biocompatible, biodegradable sustained-release implantable pharmaceutical composition of claim 1 , wherein upon implantation, the implantable composition has been shown in reference subjects to release about 1 mg adenosine per day for a time span of ten days.
6. The biocompatible, biodegradable sustained-release implantable pharmaceutical composition of claim 1 , wherein about one-third of the total adenosine in the composition is encapsulated in the microspheres.
7. The biocompatible, biodegradable sustained-release implantable pharmaceutical composition of claim 1 , wherein the scaffold comprises one or more silk fibroin coating layers comprising adenosine.
8. The biocompatible, biodegradable sustained-release implantable pharmaceutical composition of claim 1 , wherein the scaffold comprises one or more silk fibroin coating layers which comprise no added adenosine.
9. A method of treating epilepsy or preventing epileptogenesis in a subject in need thereof comprising administering directly to the brain of the subject a pharmaceutical composition comprising adenosine in a silk fibroin-based, sustained-release delivery system, wherein the silk fibroin-based, sustained delivery system comprises adenosine-encapsulating microspheres embedded in a silk fibroin scaffold and wherein the scaffold further comprises adenosine which is not encapsulated in the microsphere.
10. The method of claim 9 , wherein said delivery system has been shown in reference subjects to release from about 50 ng adenosine per day to about 50 mg adenosine per day, inclusive.
11. The method of claim 10 , wherein said delivery system has been shown in reference subjects to release from about 200 ng adenosine per day to about 5 mg adenosine per day, inclusive.
12. The method of claim 10 , wherein said delivery system has been shown in reference subjects to release at least about 1 mg adenosine per day to about 10 mg adenosine per day, inclusive.